Holen Sie sich die Stockscreener-App
12.00
3.27%
0.38
Vorhandelsmarkt:
12.10
0.10
+0.83%
Schlusskurs vom Vortag:
$11.62
Offen:
$11.63
24-Stunden-Volumen:
1.14M
Relative Volume:
1.03
Marktkapitalisierung:
$1.17B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-137.25M
KGV:
-6.3492
EPS:
-1.89
Netto-Cashflow:
$-121.97M
1W Leistung:
+14.50%
1M Leistung:
+17.30%
6M Leistung:
+115.05%
1J Leistung:
+17.07%
1-Tages-Spanne:
$11.50
$12.05
1-Wochen-Bereich:
$10.11
$12.05
52-Wochen-Spanne:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.00 | 1.13B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Is ORIC Pharmaceuticals Inc. stock poised for growth2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Identifying reversal signals in ORIC Pharmaceuticals Inc.Trade Analysis Summary & Comprehensive Market Scan Insights - newser.com
Will ORIC Pharmaceuticals Inc. stock attract ESG investorsMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
How higher bond yields impact ORIC Pharmaceuticals Inc. (4TZ) stock2025 EndofYear Setup & AI Enhanced Execution Alerts - newser.com
ORIC Pharmaceuticals Inc 4TZ Stock Analysis and ForecastMarket Correction Analysis & Expert-Backed Recommendations That Deliver - earlytimes.in
Published on: 2025-09-29 09:52:14 - newser.com
Candlestick signals on ORIC Pharmaceuticals Inc. stock todayRisk Management & Consistent Profit Alerts - newser.com
Top chart patterns to watch in ORIC Pharmaceuticals Inc.Trade Performance Summary & Growth Focused Entry Point Reports - newser.com
ORIC Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & Learn the Secrets of Pro Traders - Early Times
Merus NV and ORIC Pharmaceuticals Inc at Citi BioPharma Conferen - GuruFocus
How robust is ORIC Pharmaceuticals Inc. (4TZ) stock financial positionMarket Sentiment Summary & Breakout Confirmation Trade Signals - newser.com
Cantor Fitzgerald reiterates Overweight rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
Palumbo Wealth Management LLC Takes Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells $1,350,000.00 in Stock - MarketBeat
Rhumbline Advisers Decreases Stock Position in Oric Pharmaceuticals, Inc. $ORIC - Defense World
Should you hold or exit ORIC Pharmaceuticals Inc. now2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $17.29 Average PT from Analysts - MarketBeat
Real time scanner hits for ORIC Pharmaceuticals Inc. explainedTrade Risk Assessment & Expert Approved Momentum Trade Ideas - newser.com
How to use a screener to detect ORIC Pharmaceuticals Inc. breakoutsTake Profit & Verified Momentum Stock Ideas - newser.com
Stock Recap: What are ORIC Pharmaceuticals Incs recent SEC filings showingWeekly Investment Report & Advanced Swing Trade Entry Alerts - خودرو بانک
Is ORIC Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - newser.com
US Stocks Recap: Does ORIC Pharmaceuticals Inc. align with a passive investing strategyJuly 2025 Breakouts & Verified Momentum Watchlists - خودرو بانک
Will ORIC Pharmaceuticals Inc. outperform the marketShort Setup & Weekly Market Pulse Updates - newser.com
Risk Check: What’s ORIC Pharmaceuticals Inc.’s historical return2025 Sector Review & Smart Money Movement Tracker - خودرو بانک
How institutional ownership impacts ORIC Pharmaceuticals Inc. stockJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com
How to recover losses in ORIC Pharmaceuticals Inc. stockEarnings Risk Report & Safe Entry Zone Identification - newser.com
Quarterly Risk: Will ORIC Pharmaceuticals Inc benefit from current market trendsLayoff News & Safe Entry Point Identification - خودرو بانک
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):